Lake Y, Pinnock S
Greenlane Hospital, Auckland, New Zealand.
Aust N Z J Obstet Gynaecol. 2000 Aug;40(3):313-6. doi: 10.1111/j.1479-828x.2000.tb03341.x.
The aim of this trial was to assess the relative patient acceptability of two transdermal oestradiol patches used in treatment of oestrogen deficiency in postmenopausal women. Thirty-five hysterectomised postmenopausal women with no previous experience of transdermal oestradiol delivery systems received treatment with either once-weekly drug-in-adhesive (DIA) patches or twice-weekly reservoir patches for 4 weeks, and were then switched to the alternative treatment for a further 4 weeks. At the end of the study, the patients completed a questionnaire to assess their relative preference for a number of characteristics of the 2 transdermal systems and, where possible, their preference for transdermal compared with oral hormone replacement therapy. Thirty-one patients completed the study; four withdrew during treatment with the reservoir patch. The DIA patch was preferred for being 'easiest to remember to apply' by 80% of patients (p < 0.01), 'easiest to open' and 'easiest to apply' by 68% (p = 0.025), and as having 'best cosmetic appearance' by 65% (p = 0.05) and 'best overall skin adhesion' by 61% (p < 0.01). While 10% of patients rated the reservoir patch as 'least irritating to the skin' (p = 0.03), only one patient found this patch 'most comfortable to wear' (p < 0.01). The DIA patch was selected by 87% of patients as their preferred treatment overall (p = 0.001). Ninety-one per cent of 22 responding patients were at least as confident of treatment with transdermal patches as with oral hormone replacement therapy (p = 0.006) and 74 % of 27 responders preferred transdermal to oral treatment (p = 0.004). The DIA patch appears to be more acceptable to patients than the reservoir patch as a transdermal oestradiol delivery system for the treatment of postmenopausal oestrogen deficiency. Characteristics of the DIA patch which may account for improved patient acceptance include ease of remembering once-weekly patch application, improved cosmetic appearance and comfort, and better adhesion.
本试验旨在评估两种用于治疗绝经后女性雌激素缺乏症的经皮雌二醇贴片在患者中的相对可接受性。35名既往无经皮雌二醇给药系统使用经验的绝经后子宫切除女性接受了为期4周的治疗,她们被随机分为两组,一组使用每周一次的含药贴剂(DIA),另一组使用每周两次的储库型贴片,4周后更换为另一种治疗方式,再持续治疗4周。在研究结束时,患者完成了一份问卷,以评估她们对这两种经皮给药系统若干特性的相对偏好,以及在可能的情况下,与口服激素替代疗法相比,她们对经皮给药的偏好。31名患者完成了研究;4名患者在使用储库型贴片治疗期间退出。80%的患者认为DIA贴片“最容易记住使用”(p < 0.01),68%的患者认为其“最容易打开”和“最容易使用”(p = 0.025),65%的患者认为其“外观最好”(p = 0.05),61%的患者认为其“整体皮肤附着力最佳”(p < 0.01)。虽然10%的患者认为储库型贴片“对皮肤刺激性最小”(p = 0.03),但只有一名患者认为这种贴片“佩戴最舒适”(p < 0.01)。87%的患者选择DIA贴片作为她们总体上更偏好的治疗方式(p = 0.001)。在22名做出回应的患者中,91%的患者对经皮贴片治疗至少与口服激素替代疗法一样有信心(p = 0.006),在27名做出回应的患者中,74%的患者更喜欢经皮治疗而非口服治疗(p = 0.004)。作为一种用于治疗绝经后雌激素缺乏症的经皮雌二醇给药系统,DIA贴片似乎比储库型贴片更易被患者接受。DIA贴片可能提高患者接受度的特性包括易于记住每周一次的贴片使用、外观和舒适度改善以及附着力更好。